Clinical Trials Using Guadecitabine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Guadecitabine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-12 of 12
  • Guadecitabine and Durvalumab in Treating Patients with Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

    This phase Ib trial studies the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread to other places in the body. Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with durvalumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving guadecitabine and durvalumab may work better in treating patients with liver, pancreatic, bile duct, or gallbladder cancer.
    Location: 4 locations

  • Guadecitabine and Atezolizumab in Treating Patients with Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

    This phase I / II trial studies the side effects and best dose of guadecitabine when given together with atezolizumab and to see how well they work in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia that has spread to other places in the body and has come back or does not respond to treatment. Guadecitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of cancer cells to grow and spread. Giving guadecitabine and atezolizumab may work better in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Location: 5 locations

  • Pembrolizumab, Guadecitabine, and Mocetinostat in Treating Patients with Stage IIIb-IV Non-small Cell Lung Cancer

    This phase I / Ib trial studies the side effects and best dose of guadecitabine and mocetinostat and how well they work when given together with pembrolizumab in treating patients with stage IIIb-IV non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as guadecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Mocetinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab, guadecitabine, and mocetinostat together may work in treating patients with non-small cell lung cancer.
    Location: 3 locations

  • Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

    This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib / II study of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at the recommended phase 2 dose subcutaneously for 5 consecutive days. Eligible patients will have metastatic RCC with a clear cell component, ECOG performance status of 0-1, have received 0-1 prior therapy but no prior anti-PD-1 / PD-L1 / CTLA4 (Cohort 1, 36 subjects). Study treatment could potentially continue for up to 13 cycles (52 weeks).
    Location: 2 locations

  • Guadecitabine in Treating Patients with Wild-Type Gastrointestinal Stromal Tumor, Pheochromocytoma, Paraganglioma, or Kidney Cancer

    This phase II trial studies how well guadecitabine works in treating patients with wild-type gastrointestinal stromal tumor, pheochromocytoma, paraganglioma, or kidney cancer. Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Guadecitabine, Durvalumab, and Tremelimumab in Treating Patients with Extensive-Stage Small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of guadecitabine and to see how well it works with durvalumab and tremelimumab in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as guadecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Giving guadecitabine together with durvalumab and tremelimumab may work better in treating patients with extensive-stage small cell lung cancer.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Guadecitabine and Donor Lymphocyte Infusion in Treating Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing after Allogeneic Stem Cell Transplant

    This phase IIa trial studies how well guadecitabine works in treating patients with acute myelogenous leukemia and myelodysplastic syndrome that has returned after a period of improvement after allogeneic stem cell transplant. Guadecitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving guadecitabine before the transplant may stop this from happening. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them. Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may boost this effect.
    Location: M D Anderson Cancer Center, Houston, Texas

  • DNA Methyltransferase Inhibitor SGI-110, Donor GVAX and Cyclophosphamide in Treating Patients with Metastatic Colorectal Cancer

    This randomized pilot phase I trial studies deoxyribonucleic acid (DNA) methyltransferase inhibitor SGI-110, donor autologous granulocyte macrophage colony-stimulating factor (GM-CSF)-secreting lethally irradiated colorectal cancer cell vaccine (GVAX), and cyclophosphamide in treating patients with colorectal cancer that has spread to other places in the body. GVAX vaccine consists of two parts that are mixed together. One part of the vaccine is made from other patient's colon cancer cells and the other part is made from leukemia cells. The leukemia cells have been genetically changed, meaning that a certain gene was put into the DNA of those cells. A gene is a piece of DNA that carries a message that tells cells to make something, such as GM-CSF, a protein that has been shown to stimulate the immune response. DNA methyltransferase inhibitor SGI-110 may block abnormal cells or tumor cells from growing by blocking some of the enzymes needed for tumor growth. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide may also help the immune system respond better to treatment with the vaccine. Giving DNA methyltransferase inhibitor SGI-110 and / or cyclophosphamide together with GVAX may be a safe and successful treatment for patients with metastatic colorectal cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Guadecitabine Extension Study

    This is a multicenter, open-label extension study for subjects who participated in a previous Astex-sponsored guadecitabine clinical study (including but not limited to SGI-110-01, SGI-110-04, SGI-110-06, and SGI-110-07).
    Location: 3 locations

  • Guadecitabine and Carboplatin in Treating Patients with Extensive Stage Small Cell Lung Cancer

    This phase II trial studies how well guadecitabine and carboplatin work in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage). Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving guadecitabine and carboplatin may work better in treating patients with extensive stage small cell lung cancer compared to other standard of care chemotherapy drugs.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Atezolizumab and Guadecitabine in Treating Patients with Advanced or Metastatic Urothelial Cancer

    This phase II trial studies the side effects and best dose of atezolizumab and guadecitabine and how well they work in treating patients with urothelial cancer that has spread to other places in the body. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and guadecitabine together may work betting in treating patients with urothelial cancer.
    Location: 3 locations

  • Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This randomized phase I / IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1401 vaccine may enhance the expression of the genes encoding tumor antigens on the surface of tumor cells and enhance the activity of tumor-killing T cells against those tumor cells. Vaccines made from monoclonal antibodies combined with tumor cells may help the body build an effective immune response to kill tumor cells. Giving atezolizumab, guadecitabine, and CDX-1401 vaccine may work better than CDX-1401 alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
    Location: 16 locations